The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters
Phase 2
Completed
- Conditions
- StressSleep
- Interventions
- Drug: Caralluma FimbriataDrug: Placebo comparator - Microcrystalline cellulose
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- RDC Clinical Pty Ltd
- Target Recruit Count
- 129
- Registration Number
- NCT05232266
- Locations
- 🇦🇺
RDC Clinical Pty Ltd, Newstead, Queensland, Australia
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
Phase 3
Completed
- Conditions
- Migraine
- Interventions
- Drug: Placebo comparator - maltodextrin and microcrystalline cellulose mix
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- RDC Clinical Pty Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05046522
- Locations
- 🇦🇺
RDC Global Pty Ltd, Brisbane, Queensland, Australia
The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
Phase 2
Completed
- Conditions
- Eczema, Atopic
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- RDC Clinical Pty Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT05003453
- Locations
- 🇦🇺
RDC Global Pty Ltd, Brisbane, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath